Adaptam Therapeutics engineers antibody-based immunotherapies that disrupt the tumour microenvironment by targeting glycoimmune checkpoints selectively expressed on tumour-associated macrophages and other immunosuppressive myeloid cells. Its pipeline includes antibody-drug conjugates and bispecific antibodies designed for multiple oncology indications. The company’s science originates from research carried out at CIC bioGUNE in Bilbao and has been published in Nature Communications. Led by founder, CEO and CSO Prof. Asis Palazon, Adaptam operates from San Sebastián and Barcelona. The recent capital infusion will advance its lead programmes into preclinical development and support preparation for subsequent fundraising as it moves toward clinical trials. Previous non-dilutive backing came from a 2021 Caixa Research Health grant, alongside early support from Criteria Bio Ventures. Adaptam currently remains pre-revenue and is focused on demonstrating preclinical proof-of-concept for its platform.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2025